<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "ranitidine inj VIAL">
<dose><value>50</value>
<value>0.125</value>
<value>0.15</value>
<value>0.175</value>
<value>0.2</value>
<value>0.225</value>
<value>0.25</value>
<value>1</value>
<value>1.5</value>
<value>2</value>
<value>2.5</value>
</dose><route><value>IM</value>
<value>IV</value>
<value>IV </value>
</route><form><value>inj VIAL</value>
</form><drugname><value>ranitidine inj VIAL</value>
</drugname><strength><value>25 mg/mL</value>
</strength><frequency><value>Q6H</value>
<value>Q8H</value>
<value>CONTINUOUS</value>
<value>ONCE</value>
</frequency><instruction><value>Administer by continuous infusion for stress ulcer prophylaxis</value>
<value>Administer by continuous infusion for hypersecretory conditions.</value>
<value>Administer 1 hour pre-operatively.</value>
<value>DAY 1 of 21. If oral ranitidine has not been taken by patient as instructed, administer 30 minutes pre-PACLitaxel. May be administered by PO route.</value>
<value>DAY 1 of 21. May be administered by PO route.</value>
<value>DAY 1 of 7. If oral ranitidine has not been taken by patient as instructed, administer 30 minutes pre-PACLitaxel. May be administered by PO route.</value>
<value>DAY 1 of 7. May be administered by PO route.</value>
</instruction><volume><value>2 mL</value>
<value>40 mL</value>
</volume><units><value>mg</value>
<value>mg/kg/hour</value>
</units><additionalnotes><value>stress ulcer prophylaxis</value>
</additionalnotes><population><value>Adjuvant PACLitaxel/CARBOplatin. Non-Small Cell Lung Cancer</value>
<value>PACLitaxel / CARBOplatin. Advanced / Metastatic Non-Small Cell Lung Cancer</value>
<value>PACLitaxel/CARBOplatin (Weekly) and concurrent RT. Non-Small Cell Lung Cancer.</value>
</population><indicationprn></indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=1685</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=1686</value>
</backgroundinformation><prninformation><value>YES</value>
</prninformation><ahsformularystatus><value>Formulary with Therapeutic Interchange.</value>
</ahsformularystatus><ahfsname><value>Antiulcer Agents and Acid Suppressants, Histamine H2-Antagonists</value>
</ahfsname><highalert></highalert><maximumprndose></maximumprndose><din><value>02212366</value>
</din></drug>